Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00023647 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage IV Melanoma
A Phase 1 study, sponsored by Mannkind Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00023647 is a Phase 1 study that has completed, run by Mannkind Corporation. The registered enrollment target is 26 participants.
The verdict
NCT00023647, a Phase 1 study, has completed, sponsored by Mannkind Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy given directly into a lymph node in treating patients who have stage IV melanoma.
Interventions
- BIOLOGICAL Synchrotope TA2M
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2000-07 |
| Est. Completion | 2002-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00023647
The ClinicalTrials.gov registry entry for NCT00023647 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mannkind Corporation, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Synchrotope TA2M is the first listed.
NCT00023647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00023647 about?
NCT00023647 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IV Melanoma". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Infusing the vaccine directly into a lymph node may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy given directly into a lymph node i...
What is the current status of trial NCT00023647?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2000-07. Estimated completion is 2002-11.
What interventions are being tested in trial NCT00023647?
The interventions under investigation include: Synchrotope TA2M (BIOLOGICAL).
Who is sponsoring clinical trial NCT00023647?
This trial is sponsored by Mannkind Corporation, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.